Famous Patents
In 1879, Auguste Bartholdi received design patent number 11,023 titled "Design for a Statue". It was for the Statue of Liberty.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7572882 | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates ou... | 08/11/2009 |
| 7452963 | Replikin peptides and antibodies therefore The present invention provides a new class of peptides related to rapid replication and their use in diagnosing, preventing and treating disease. ... | 11/18/2008 |
| 7442761 | Replikin peptides and uses thereof The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease. ... | 10/28/2008 |
| 7425618 | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no ... | 09/16/2008 |
| 7420028 | Replikins and methods of identifying replikin-containing sequences The present invention provides methods for identifying a class of peptides referred to as replikins and methods of using replikins to stimulate the immune system of a subject. The method of identifying replikin peptides is based on identifying amino acid sequences c... | 09/02/2008 |
| 7413889 | Production of a parvovirus vaccine in plants as viral coat protein fusions The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusio... | 08/19/2008 |
| 7407744 | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors A global functional analysis of HCMV genes is performed by constructing virus gene-deletion mutants and examining their growth phenotypes in different natural HCMV host cells. This systematic analysis of the HCMV genome identified 45 viral ORFs essential for viral r... | 08/05/2008 |
| 7402396 | Core structure of gp41 from the HIV envelope glycoprotein Described are the crystal structure of the α-helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so. ... | 07/22/2008 |
| 7371392 | Cd40 ligand adjuvant for respiratory syncytial virus The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising... | 05/13/2008 |
| 7368537 | Subunit vaccine against respiratory syncytial virus infection The present invention relates generally to methods of treating or preventing RSV infections, and more specifically, to compositions, and the use thereof, comprising one or more RSV G protein immunogen or fragment thereof capable of eliciting protective immunity with... | 05/06/2008 |
| 7361496 | Rescue of mumps virus from cDNA This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus... | 04/22/2008 |
| 7329408 | Eliciting HCV-specific antibodies Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E... | 02/12/2008 |
| 7316813 | Influenza vaccine composition An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by a SRD assay. The influenza virus preparation may com... | 01/08/2008 |
| 7312064 | DNA transfection system for the generation of infectious influenza virus The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably ... | 12/25/2007 |
| 7291453 | Viral variants The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting comp... | 11/06/2007 |
| 7285401 | Method and reagents for detecting nucleic acid sequences The present invention is directed to a method for detecting an amplification product. Amplification is accomplished through the use of a plurality of detection probes. The present invention is also directed to a method for detecting a target nucleic acid sequence by... | 10/23/2007 |
| 7282364 | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides enc... | 10/16/2007 |
| 7276579 | Immunogenic proteoliposomes, and uses thereof An immunogenic proteoliposome containing a transmembrane protein or oligomeric complexes containing such proteins, including viral envelope glycoproteins, in a lipid membrane around an elliptoid or spherical shape. The shape preferably also contains an attractant su... | 10/02/2007 |
| 7264957 | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a PRRSV and a method of detecting a PRRSV The present invention provides a purified preparation containing a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and resp... | 09/04/2007 |
| 7262292 | Oligonucleotides and methods for detecting hepatitis B viral nucleic acids The present invention provides methods and compositions for determining the presence and/or amount of HBV nucleic acids in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and qu... | 08/28/2007 |
| 7262267 | Polypeptide mediating cell permeability The present invention relates to a cell-permeable polypeptide that can mediate cell permeability to substances, DNA coding for said polypeptide and a method for the production of said polypeptide. The invention also relates to antibodies directed against the polypep... | 08/28/2007 |
| 7238777 | Agents for adsorption and bridging for adenovirus The object of the present invention is to provide an agent for specific adsorption of type 5 adenoviral vector to undifferentiated blood cells which enables infection with a viral concentration that does not impart toxicity to undifferentiated blood cells, without r... | 07/03/2007 |
| 7230084 | Therapeutic using a bispecific antibody Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or dia... | 06/12/2007 |
| 7226780 | Lentivirus vector system A method is disclosed for improving encapsidation of transgene RNA using retroviral packaging and transfer vectors. An HIV-2 transfer vector, which includes the transgene, is introduced into a packaging cell that is also transfected with (or stably expresses) an HIV... | 06/05/2007 |
| 7227001 | Manganese superoxide dimutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms A new isoform of manganese superoxide dismutase (MnSOD) and polynucleotides encoding it have been identified. This isoform, MnSOD E3(−), is a splice variant lacking exon 3 of the full length MnSOD. The polypeptide can be expressed using appropriate host cells. Mod... | 06/05/2007 |
| 7223584 | Recombinant rabies vaccine and methods of preparation and use Live rabies virus vaccines comprising a recombinant rabies virus genome which overexpresses the rabies virus G protein increase apoptotic activity in infected cells, and enhance the generation of anti-rabies immunity in a subject. ... | 05/29/2007 |
| 7217784 | VP1 of foot-and-mouth disease virus A pure, water-soluble polypeptide containing one or more monomers of a VP1 protein of a foot-and-mouth disease virus; or a pure, water-insoluble polypeptide comprising two or more monomers of a VP1 protein of a foot-and-mouth disease virus. Also disclosed are a vacc... | 05/15/2007 |
| 7214524 | Marek's disease virus vaccine An effective vaccine for Marek's disease may be prepared using a viral agent which is a Marek's disease virus unable to express a functional meq protein. This viral agent is effective to elicit an immune response in a chicken to very virulent strains of Marek's dise... | 05/08/2007 |
| 7208167 | Treatment of hepatitis C with thymosin and peptide combination therapy A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with administration to the hepatitis C patient of an effective amount of at least on... | 04/24/2007 |
| 7208162 | Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibo... | 04/24/2007 |
| 7192759 | Production of vaccines Novel means and methods are provided for the production of mammalian viruses comprising, infecting a culture of immortalized human cells with the virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the viru... | 03/20/2007 |
| 7189800 | Replikin peptides in rapid replication of glioma cells and in influenza epidemics Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influe... | 03/13/2007 |
| 7148329 | Composition and method for modulating dendritic cell-t cell interaction The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another ma... | 12/12/2006 |
| 7148325 | Chimeric retroviral gag genes and screening assays The subject invention provides novel and advantageous methods for identifying amino acid sequences in random peptide libraries that can bind to Gag polypeptides. The subject invention also establishes a novel in vitro system that can be used to test competitive inhi... | 12/12/2006 |
| 7144994 | Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms A new isoform of manganese superoxide dismutase (MnSOD) and polynucleotides encoding it have been identified. This isoform, MnSOD E3(−), is a splice variant lacking exon 3 of the full length MnSOD. The polypeptide can be expressed using appropriate host cells. Mod... | 12/05/2006 |
| 7132277 | Helper dependent vector system for gene therapy The present invention features helper-dependent adenoviral vector elements, and helper adenoviral elements, that enhance the production and isolation of helper-dependent adenoviral vectors. Such elements include a modified packaging signal having low homology to, an... | 11/07/2006 |
| 7125971 | Full-length genomic RNA of papaya leaf-distortion mosaic virus The purpose of the present invention is to determine the nucleotide sequence of the full-length genomic RNA of papaya leaf-distortion mosaic virus. The present invention provides the full-length genomic RNA of papaya leaf-distortion mosaic virus, a method for diagno... | 10/24/2006 |
| 7118888 | Gene expression vaccine An effective prophylactic mucosal gene expression vaccine (GXV), made up of a cocktail of at least 4 different plasmid DNAs encoding corresponding RSV antigens, coacervated with chitosan to formulate nanospheres. In a murine model of RSV infection, intranasal admini... | 10/10/2006 |
| 7109025 | Viral vectors and viral vaccines based on recombinant porcine adenoviruses An in vivo replicative and recombined porcine adenovirus characterized in that it comprises a heterologous nucleotide sequence inserted into the porcine adenovirus in conditions enabling the latter to be replicated in vivo and to express the inserted heterologous nu... | 09/19/2006 |
| 7105303 | Antibodies to hepatitis C virus asialoglycoproteins Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more simi... | 09/12/2006 |
